| scholarly article | Q13442814 |
| P2093 | author name string | Ira J Goldberg | |
| P2860 | cites work | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 |
| Biochemistry and molecular cell biology of diabetic complications | Q28131781 | ||
| Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association | Q33728882 | ||
| Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) | Q33764951 | ||
| The effect of alloxan diabetes on experimental cholesterol atherosclerosis in the rabbit. IV. The effect of insulin therapy on the inhibition of atherosclerosis in the alloxan-diabetic rabbit | Q36262471 | ||
| Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus | Q37239783 | ||
| Increased atherosclerosis in streptozotocin-induced diabetic mice | Q37353969 | ||
| Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions | Q37486465 | ||
| Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. | Q38299150 | ||
| Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts | Q41009444 | ||
| Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits | Q41418248 | ||
| Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-ric | Q41664275 | ||
| Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice | Q44007466 | ||
| Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice | Q45120387 | ||
| Effect of hyperglycemia and hyperlipidemia on atherosclerosis in LDL receptor-deficient mice: establishment of a combined model and association with heat shock protein 65 immunity. | Q51555624 | ||
| Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. | Q54060454 | ||
| Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial | Q72198055 | ||
| Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice. Effects on lipoproteins and atherosclerosis | Q73251589 | ||
| Neointimal formation after endovascular arterial injury is markedly attenuated in db/db mice | Q79074129 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 613-615 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Why does diabetes increase atherosclerosis? I don't know! | |
| P478 | volume | 114 |
| Q26866336 | ADIPOQ and adiponectin: the common ground of hyperglycemia and coronary artery disease? |
| Q36823761 | Adiponectin gene and cardiovascular risk in type 2 diabetic patients: a review of evidences. |
| Q35800420 | Advanced glycation end products (AGEs) in relation to atherosclerotic lipid profiles in middle-aged and elderly diabetic patients |
| Q37267563 | Advanced glycation end products increase lipids accumulation in macrophages through upregulation of receptor of advanced glycation end products: increasing uptake, esterification and decreasing efflux of cholesterol |
| Q60364605 | Advanced glycation end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models |
| Q40117639 | Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. |
| Q35832106 | Angiogenic transforming capacity of IgG purified from plasma of type 1 diabetic patients |
| Q41894332 | Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products |
| Q46655999 | Characterisation of atherosclerotic lesions with scanning electron microscopy (SEM) of wet tissue |
| Q35161203 | DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice |
| Q36981806 | Diabetes and the heart: could the diabetic myocardium be protected by preconditioning? |
| Q53486855 | Diabetes with poor glycaemic control does not promote atherosclerosis in genetically modified hypercholesterolaemic minipigs. |
| Q33414830 | Early atherosclerosis and vascular inflammation in mice with diet-induced type 2 diabetes |
| Q35873096 | Elevated Glucose Levels Promote Contractile and Cytoskeletal Gene Expression in Vascular Smooth Muscle via Rho/Protein Kinase C and Actin Polymerization |
| Q41903989 | Endothelial dysfunction in adiponectin deficiency and its mechanisms involved |
| Q36423339 | Genetics of macrovascular complications in diabetes |
| Q42153827 | Global gene expression profiling displays a network of dysregulated genes in non-atherosclerotic arterial tissue from patients with type 2 diabetes |
| Q27024469 | Glycemic control and cardiovascular disease: what's a doctor to do? |
| Q37636425 | Hepatic transforming growth factor-β 1 stimulated clone-22 D1 controls systemic cholesterol metabolism |
| Q24530027 | Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice |
| Q34698828 | Insulin resistance and pancreatic beta cell failure |
| Q37386451 | Intercellular communication in atherosclerosis. |
| Q26766350 | Large animal models of cardiovascular disease |
| Q46034532 | Peripheral arterial disease and clinical risks in Taiwanese hemodialysis patients. |
| Q43245613 | Persistent arterial stiffness and endothelial dysfunction following successful pancreas-kidney transplantation in Type 1 diabetes. |
| Q38628797 | Potential therapeutic effects of mTOR inhibition in atherosclerosis. |
| Q37860348 | RAGE biology, atherosclerosis and diabetes |
| Q36074880 | Reduced alpha-lipoic acid synthase gene expression exacerbates atherosclerosis in diabetic apolipoprotein E-deficient mice |
| Q92045276 | Risk Factors for Restenosis After Carotid Revascularization: A Meta-Analysis of Hazard Ratios |
| Q46506824 | The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation |
| Q34729946 | The bitter fate of the sweet heart: impairment of iron homeostasis in diabetic heart leads to failure in myocardial protection by preconditioning |
| Q37195072 | Type 2 diabetes, mitochondrial biology and the heart |
Search more.